Jascayd: EU approval marks new chapter in pulmonary fibrosis, says GlobalData
Jascayd is a first-in-class phosphodiesterase 4B (PDE4B) inhibitor that has been designed to have isoform selectivity to retain the antifibrotic and anti-inflammatory effects of PDE4 inhibition while avoiding the tolerability constraints that have limited previous nonselective PDE4 inhibitors in respiratory diseases
August 4, 2026